Document Detail


Effects of "systemic" budesonide concentrations on in vitro allergen-induced activation of blood mononuclear cells isolated from asthmatic patients.
MedLine Citation:
PMID:  7573828     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Blood levels of inhaled corticosteroids are significantly lower than those measured in the lung, but their concentration could still have anti-inflammatory effects. To determine whether budesonide, at concentrations similar to those obtained in blood after drug inhalation (10(-9) M), could downregulate the allergen-induced activation of mononuclear cells, we studied 21 atopic patients, sensitized to Dermatophagoides pteronyssinus (Der p). On blood mononuclear cells, isolated from these patients, incubated with Der p allergen extract and with or without budesonide, we evaluated: 1) the proliferative response of T cells; 2) the expression of two surface activation markers, the HLA-DR antigens and the interleukin (IL)-2 receptors; and 3) the release of cytokines known to modulate the allergic processes. Allergen-induced T-cell proliferation was associated with increased HLA-DR antigen and IL-2 receptor expression (P < 0.001), and with increased release of IL-2, interferon-gamma (IFN-gamma), IL-1 beta, tumor necrosis factor-alpha (TNF-alpha), and granulocyte/macrophage colony-stimulating factor (GM-CSF). The addition of budesonide at the beginning of the cell cultures induced a dose-dependent inhibition of T-cell proliferation, still significant (P < 0.05) at the lowest concentrations tested (10(-9) and 10(-10) M). A significant inhibitory effect on T-cell proliferation was also present when budesonide (10(-9) M) was added to the cell cultures 3 or 5 days after the beginning of the cell cultures.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
S Oddera; M Silvestri; O Sacco; S Lantero; M C Morelli; G A Rossi
Related Documents :
11237178 - Recent topics in anti-oxidative factors.
9048228 - Classification of chemical allergens according to cytokine secretion profiles of murine...
20118218 - Allergy risk is mediated by dendritic cells with congenital epigenetic changes.
12445798 - Interleukin-13 induces thymus and activation-regulated chemokine (ccl17) in human perip...
24217808 - In vivo comparison of local versus systemic delivery of immunostimulating sirna in hpv-...
8898208 - Dissection of tnf receptor 1 effector functions: jnk activation is not linked to apopto...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Allergy     Volume:  50     ISSN:  0105-4538     ISO Abbreviation:  Allergy     Publication Date:  1995 May 
Date Detail:
Created Date:  1995-11-02     Completed Date:  1995-11-02     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7804028     Medline TA:  Allergy     Country:  DENMARK    
Other Details:
Languages:  eng     Pagination:  397-404     Citation Subset:  IM    
Affiliation:
Division of Pneumology, G. Gaslini Institute, Genoa, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Allergens / immunology*
Antigens, Dermatophagoides
Asthma / blood*,  immunology*
Budesonide
Cell Separation
Cytokines / metabolism
Female
Glucocorticoids / administration & dosage*,  therapeutic use
Glycoproteins / immunology
HLA-DR Antigens / immunology
Humans
Lymphocyte Activation* / drug effects
Male
Monocytes / immunology*,  metabolism
Osmolar Concentration
Pregnenediones / administration & dosage*,  therapeutic use
Receptors, Interleukin-2 / immunology
T-Lymphocytes / immunology
Chemical
Reg. No./Substance:
0/Allergens; 0/Antigens, Dermatophagoides; 0/Cytokines; 0/Glucocorticoids; 0/Glycoproteins; 0/HLA-DR Antigens; 0/Pregnenediones; 0/Receptors, Interleukin-2; 51333-22-3/Budesonide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Type III allergy skin testing. Position statement for EAACI Subcommittee on Skin Tests and Allergen ...
Next Document:  Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study.